QTORIN rapamycin 3.9 percent gel

Microcystic lymphatic malformations

Manufacturer: Palvella Therapeutics
Regulatory submission: NDA submitted August 2026
Launch: Anticipated in the first half of 2027
Last updated: September 19, 2026

Section

Product information and disease description Place of product in therapy Approaches to treatment Current treatment options and standard of care

Sclerotherapy

1 evidence topic · 1 source

Guideline-listed treatment for skin and mucosal lymphatic malformations

“sclerotherapy” (opens the source at this quote in a new tab)